Investor Relations
Reporting
Evonik has published its quarterly report Q4 2020 on March 4, 2021. You can access further information here. ... MORE
Investor Relations
Annual Shareholders’ Meeting 2021
The Annual Shareholders‘ Meeting 2021 of Evonik Industries AG will take place on June 2, 2021 at 10 a.m (Central European Summer Time - CEST). We will publish further information soon. ... MORE
Investor Relations
Division Spotlight Series
We will be hosting a virtual "Division Spotlight Series" for our three growth divisions over the first half of 2021. ... MORE
Further Information
Company
Events & Presentations
Here you will find dates, information and presentations on our events. ... MORE
Company
Analysts' estimates
Evonik Industries AG is covered by German and international financial analysts, who provide their own research analyses and earnings estimates in respect of the company. ... MORE
Company
News & Reports
Here you can find "Investor Relations News" with the latest news from our company, plus our most recent interim reports, annual reports and corporate responsibility reports. ... MORE
Reporting 2021
-
May 6, 2021Quarterly Report Q1 2021
-
June 2, 2021Annual Shareholders' Meeting
-
August 5, 2021Quarterly Report Q2 2021
-
November 4, 2021Quarterly Report Q3 2021
Investor Relations
Mar 04, 2021
Evonik gets through the pandemic well, is back on course for growth
Essen, Germany. Evonik has achieved the financial targets it set itself in May 2020. ... MORE
Investor Relations
Feb 25, 2021
Award for sustainability: Platinum rating for Evonik
Essen, Germany. The EcoVadis rating agency has awarded Evonik a "platinum" rating for its sustainability performance for the first time. ... MORE
Investor Relations
Feb 11, 2021
Evonik strengthens strategic partnership with BioNTech on COVID-19 vaccine
Evonik is investing in the short-term expansion of its specialty lipids production which are essential for mRNA-based COVID-19 vaccines. ... MORE
Investor Relations
Dec 07, 2020
Fight against COVID-19: Evonik supplies key technology for gene-based drugs
The COVID-19 pandemic has prompted a breakthrough in gene-based vaccines using a technology in which Evonik is a global leader ... MORE
Investor Relations
Nov 12, 2020
Evonik to complete the consolidation of its European production network for household care products this month
Evonik will this month complete the consolidation of its European manufacturing activities for fabric softener ingredients to its world-class production sites ... MORE
Investor Relations
Nov 03, 2020
Evonik successfully completes acquisition of Porocel
On November 3, 2020, Evonik completed the acquisition of the Porocel Group, Houston (USA), for US$ 210 million, as planned. ... MORE
Further Information
Company
Financial data
Evonik is active in over 100 countries around the world. In fiscal 2018 more than 36,000 employees generated sales of €15 billion and an operating profit (adjusted EBITDA) of €2.6 billion. ... MORE
Company
Bonds & Rating
Evonik maintains a centralized approach to financing. Liabilities for credit and loans are fully guaranteed by Evonik Industries AG. ... MORE
Company
Key Figures Share
Here you find information about Evonik shares. ... MORE
Company
Contact & Service
You can find the contacts in the Investor Relations Department here. ... MORE
Company
Disclaimer
Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained. ... MORE
Company
Corporate Governance
As a globally active company, we have to comply with a wide range of statutory regulations and cultural standards. ... MORE
Investor Relations
Sustainable Investment (SRI)
We accept responsibility for our businesses, our employees, the environment and the society. ... MORE